Biotech: Page 2
-
Permission granted by Biogen
What’s driving pharma’s layoffs in 2025
Familiar foes in the industry have claimed a slew of jobs in recent months.
By Meagan Parrish • March 10, 2025 -
iStock via Getty Images
The time is ripe for pharma M&A. Why are drugmakers holding out?
The M&A resurgence has been predicted for years, but the industry is still holding out, partly because the ideal range for biotech valuations has been harder to find.
By Michael Gibney • March 6, 2025 -
Explore the Trendline➔
Stock via Getty Images
TrendlineTech for Clinical Trials
Companies that utilize these emerging technologies wisely are likely to find an edge in the increasingly competitive drug development arena.
By PharmaVoice staff -
Mario Tama via Getty Images
With patent losses on the horizon, Amgen refocuses its business strategy
The company's vice president and general manager of U.S. business operations explains how Amgen is going to deliver on its “ambitious growth aspirations.”
By Alexandra Pecci • March 5, 2025 -
Permission granted by Voyager Therapeutics
New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer’s approach
Voyager Therapeutics’ progress with drug candidates targeting tau marks a step in how the industry is walking multiple paths toward new therapeutic options.
By Michael Gibney • March 4, 2025 -
Permission granted by Recursion
Q&AAI deals are surging, and Recursion’s ongoing Exscientia merger points to a new world of integration
Recursion CFO Ben Taylor discusses the state of AI M&A and what companies should look for as the industry moves to new data technologies and systems.
By Michael Gibney • Feb. 27, 2025 -
Getty Images via Getty Images
Cancer vaccines have stumbled, but the approach is gaining new steam
The number of candidates in development has nearly doubled over the past 15 years.
By Kelly Bilodeau • Feb. 26, 2025 -
Stock via Getty Images
Its CEO died. The company scrapped a promising program. Now, for their 2nd act.
Terns Pharmaceuticals sees blockbuster promise for two potential best-in-class molecules in obesity and oncology.
By Alexandra Pecci • Feb. 25, 2025 -
Getty Images via Getty Images
Incentivizing rare disease R&D is getting tougher, but revamped policies could turn the tide
Orphan drug development has long been incentivized by government policy. But as the financial math shifts, so do the risks of bringing rare disease drugs to market.
By Michael Gibney • Feb. 25, 2025 -
Permission granted by Immunocore
Q&A // First 90 DaysLilly’s former M&A chief scours the landscape for potential deals as Immunocore’s new CFO
Travis Coy is using his Big Pharma bona fides to prioritize business development at the diversified and growing company.
By Michael Gibney • Feb. 20, 2025 -
Stock via Getty Images
Biotech SpotlightCRISPR’s cardio catch-all drives a biotech’s broad potential
Scribe Therapeutics hopes to prevent cardiometabolic diseases by targeting underlying causes with CRISPR technology.
By Kelly Bilodeau • Feb. 18, 2025 -
Stock via Getty Images
Salesforce or Veeva: How drugmakers can navigate the upcoming CRM split
The two companies will let their long-running contract expire this year, and drugmakers will need to decide which is the best platform for them in a changing marketplace.
By Michael Gibney • Feb. 13, 2025 -
Stock via Getty Images
In the crowded cardio space, it’s David vs. Goliath for small biotechs
What will it take for a clinical-stage biotech to break into the cardio space? One CEO thinks he has the answer.
By Alexandra Pecci • Feb. 11, 2025 -
Permission granted by Fractyl Health
Q&A // Biotech SpotlightBeyond GLP-1s? This biotech is exploring longer-term metabolic treatments
Fractyl Health is entering pivotal studies for a procedure that aims to be an ‘off ramp’ to GLP-1s and exploring how a one-time, ‘smart GLP-1’ gene therapy can Treat type 2 diabetes.
By Amy Baxter • Feb. 10, 2025 -
Stock via Getty Images
As financial headwinds pick up, pharmas are aiming to squeeze more ROI from their R&D
With assets under a knife and pipelines under a microscope, R&D programs are being overhauled to be more efficient and cost effective.
By Alexandra Pecci • Feb. 5, 2025 -
David McNew via Getty Images
Drugmakers prep for bird flu outbreak, despite continued low risk
While the virus hasn’t made a sustained leap into humans, vaccines and treatments are coming through the pipes if it does.
By Kelly Bilodeau • Feb. 3, 2025 -
Stock via Getty Images
Year in PreviewPharma’s forecast for 2025: Sowing seeds of a rebound
Despite regulatory uncertainty, pharma is bouncing back from a market slump and is being fueled by innovation.
By Meagan Parrish • Jan. 31, 2025 -
Courtesy of Vertex Pharmaceuticals
A long-awaited alternative to opioids is on the FDA doorstep. Can Vertex seal the deal?
Vertex Pharmaceuticals’ non-opioid pain medication is up for FDA approval this week. Other drugmakers have found safer alternatives to expand the pain management landscape.
By Amy Baxter • Updated Feb. 4, 2025 -
Permission granted by Klein Hersh
Executive hiring changes reflect a broader biotech comeback
Executive hiring shifts are often indicators of wider trends in the market. Here’s how the hiring landscape for pharma leaders is changing.
By Alexandra Pecci • Jan. 29, 2025 -
Stock via Getty Images
Natural killer cells, a rising alternative to CAR-T cell therapy
These innate immune cells may provide a safer, lower-cost option in cancer and autoimmune diseases.
By Kelly Bilodeau • Jan. 27, 2025 -
Stock via Getty Images
Gene therapies have been uneven for DMD — but these companies hope to turn the tide
Despite mixed results using gene therapies to treat Duchenne muscular dystrophy, drug developers are pushing ahead with the belief the answer could come down to delivery.
By Meagan Parrish • Jan. 24, 2025 -
E+ via Getty Images
J&J is all in on tau-targeted Alzheimer’s candidates. Will the approach lead to more effective treatments?
Anti-tau candidates haven’t crossed the regulatory threshold like their anti-amyloid counterparts, but J&J’s clinical efforts could lead in the right direction.
By Michael Gibney • Jan. 23, 2025 -
Permission granted by BioAge Labs
After an obesity stumble, BioAge reconnects with its longevity pipeline
The company is kicking off the year with a new Novartis partnership and renewed focus on metabolic aging targets.
By Alexandra Pecci • Jan. 22, 2025 -
Nikida via Getty Images
Deep Dive‘The bar has risen’: China’s biotech gains push US companies to adapt
Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder.
By Ben Fidler • Jan. 17, 2025 -
Anna Moneymaker via Getty Images
Musk’s rare disease torpedo, hospitals’ pharma fix and other policies leaders are tracking
There’s more to pharma's regulatory story in 2025 than just the IRA.
By Meagan Parrish • Jan. 17, 2025 -
Jason Doiy / Getty Images via Getty Images
By the numbers: J&J, GSK lead J.P. Morgan deal announcements in 2025, the largest turnout in years
The J.P. Morgan Healthcare Conference has been a focal point for M&A year after year, and after a quiet period, the deals are back on the table.
By Michael Gibney • Jan. 16, 2025
Previous
